Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features

Published:2017-09 Issue:3 Volume:153 Page:812-826
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Sia Daniela,Jiao Yang,Martinez-Quetglas Iris,Kuchuk Olga^ORCID,Villacorta-Martin Carlos^ORCID,Castro de Moura Manuel^ORCID,Putra Juan,Camprecios Genis,Bassaganyas Laia,Akers Nicholas^ORCID,Losic Bojan,Waxman Samuel,Thung Swan N.,Mazzaferro Vincenzo,Esteller Manel^ORCID,Friedman Scott L.,Schwartz Myron,Villanueva Augusto^ORCID,Llovet Josep M.

Funder

Tisch Cancer Institute

US Department of Defense

European Commission Framework Program 7

Horizon 2020 Program

Asociación Española Contra el Cáncer

Samuel Waxman Cancer Research Foundation

Spanish National Health Institute

Grup de Recerca Consolidat–Recerca Translacional en Oncologia Hepàtica

AGAUR

European Commission HEPCAR

Onlus Prometeo

Hepato-Oncology Research Project

Istituto Nazionale Tumori

National Cancer Institute

IRCCS Foundation

Juan de la Cierva Fellowship

Associazione Italiana per la Ricerca sul Cancro

Italian Ministry of Health

National Institutes of Health

American Association

Liver Diseases Foundation Alan Hofmann Clinical and Translational Award

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference42 articles.

1. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010;Murray;Lancet,2012

2. Hepatocellular carcinoma;Llovet;Nat Rev Dis Primers,2016

3. Genetic landscape and biomarkers of hepatocellular carcinoma;Zucman-Rossi;Gastroenterology,2015

4. Sorafenib in advanced hepatocellular carcinoma;Llovet;N Engl J Med,2008

5. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial;Bruix;Lancet,2017

Cited by 677 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for hepatocellular carcinoma;JHEP Reports;2024-10

2. Specific features of ß-catenin-mutated hepatocellular carcinomas;British Journal of Cancer;2024-09-11

3. Identification of two heterogeneous subtypes of hepatocellular carcinoma with distinct pathway activities and clinical outcomes based on gene set variation analysis;Frontiers in Genetics;2024-09-10

4. Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment;Frontiers in Immunology;2024-09-03

5. Radio-immunomics in hepatocellular carcinoma: Unraveling the tumor immune microenvironment;Meta-Radiology;2024-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3